GILD
GILEAD SCIENCES, INC.
Nasdaq: GILD · Foster City, CA · Healthcare
$156.04-1.15 (-0.73%)Closed
Market Cap$193.65B
Cash$5.41Bmost recent
Runwayprofitable
P/E (TTM)23.0EPS $6.78
52-Wk Range$115.04 – $157.37
Avg Volume6.8M3-month
Price & Trading Activity

Daily close with catalyst overlays and trading volume

$156.04+85.5%
Pipeline

Drug candidates sponsored by GILEAD SCIENCES · ClinicalTrials.gov

71 drugs · 100 trials
PhaseDrug / CandidateIndicationsStatusNext CompletionTrials
Phase 4Truvada
HIV-1
Completed
2008-03past
1
Phase 4Truvada (TDF+FTC) alone
HIV Infections
Completed
2008-05past
1
Phase 4Atripla
HIV Infections
Completed
2009-10past
1
Phase 4Sofosbuvir
Hepatitis C Virus Infection+2 more
Completed
2015-06past
2
Phase 4Ambisome
Leukemia
Completed—1
Phase 3Viread (tenofovir disoproxil fumarate)
HIV Infections
Completed
2001-12past
1
Phase 3AZLI 75 mg two times a day (BID)/three times a day (TID)
Cystic Fibrosis
Completed
2006-09past
1
Phase 3Darusentan
Hypertension
Terminated
2010-02past
1
Phase 3FTC/RPV/TDF
HIV-1 Infection
Completed
2012-01past
1
Phase 2EVG/COBI/FTC/TDF
Acquired Immunodeficiency Syndrome+1 more
Completed
2015-10-22past
1
Phase 3IMMU-107
Metastatic Pancreatic Cancer+1 more
Terminated
2016-11past
1
Phase 3Eleclazine
Long QT Syndrome Type 3+1 more
Completed
2016-12-12past
2
Phase 3LDV/SOF
Chronic Hepatitis C Virus+4 more
Completed
2017-02-14past
5
Phase 3F/TAF
HIV-1 Infection
Completed
2017-12-11past
1
Phase 3SOF/VEL
Hepatitis C Virus Infection
Completed
2018-02-13past
2
Phase 3Idelalisib
Chronic Lymphocytic Leukemia+6 more
Completed
2018-06-18past
5
Phase 3TAF
HBV+3 more
Completed
2018-09-10past
3
Phase 3Ambrisentan
Pulmonary Hypertension
Completed
2019-09-11past
1
Phase 3E/C/F/TAF
HIV-1 Infection+2 more
Completed
2020-05-11past
2
Phase 3AZLI
Pseudomonas Aeruginosa Respiratory Tract Infection/Colonization+1 more
Terminated
2020-05-27past
1
Phase 3Filgotinib
Rheumatoid Arthritis+1 more
Completed
2023-01past
2
Phase 3Seladelpar 10 mg
Primary Biliary Cholangitis
Completed
2023-08-11past
1
Phase 3Obeldesivir
COVID-19+3 more
Completed
2025-12past
4
Phase 3ISL/LEN
HIV-1-infection
Active, not recruiting
2026-04-17past
1
Phase 3Sacituzumab Govitecan-hziy
Metastatic Breast Cancer+6 more
Active, not recruiting
2027-05
3
Phase 3Zimberelimab
Non-small Cell Lung Cancer
Active, not recruiting
2028-06
1
Phase 2Lenacapavir
HIV-1-infection+1 more
Active, not recruiting
2030-07
2
Phase 2Tecadenoson
Atrial Fibrillation
Completed
2008-04past
1
Phase 2Placebo
Hyperlipidemia
Completed
2008-08past
1
Phase 1Tenofovir DF
HIV Infections+1 more
Completed
2012-02past
2
Phase 2GS-5885 tablet
Chronic Genotype 1a or 1b HCV Infection
Completed
2013-01past
1
Phase 1milatuzumab
Chronic Lymphocytic Lymphoma
Completed
2013-01past
1
Phase 2Simtuzumab
Pancreatic Cancer
Completed
2013-10past
1
Phase 2SEL
Non-Alcoholic Steatohepatitis (NASH)
Completed
2016-10-11past
1
Phase 2Presatovir
Respiratory Syncytial Virus (RSV)+1 more
Completed
2017-04-17past
2
Phase 2SOF
Hepatitis C+1 more
Completed
2017-06-05past
2
Phase 1Sacituzumab Govitecan-hziy (SG)
Gastric Adenocarcinoma+15 more
Completed
2019-03-01past
1
Phase 2Lanraplenib
Cutaneous Lupus Erythematosus
Completed
2019-03-13past
1
Phase 2Tirabrutinib
Chronic Lymphocytic Leukemia
Completed
2019-06-17past
2
Phase 2Inarigivir Soproxil
Chronic Hepatitis B
Terminated
2020-01-20past
1
Phase 2GS-5718
Rheumatoid Arthritis
Withdrawn
2023-02past
1
Phase 2Magrolimab
Solid Tumor+2 more
Completed
2024-10-01past
3
Phase 2Tilpisertib Fosmecarbil
Ulcerative Colitis
Active, not recruiting
2027-01
1
Phase 2Oral Lenacapavir
HIV-1-infection+1 more
Recruiting
2027-03
2
Phase 2Denikitug
Advanced Microsatellite Stable Colorectal Cancer
Recruiting
2028-12
1
Phase 2TUB-040
NSCLC+1 more
Not yet recruiting
2029-05
1
Phase 2Nelfinavir mesylate
HIV Infections
Completed—2
Phase 2BSF 208075
Pulmonary Hypertension
Completed—1
Phase 1hMN14 (labetuzumab)
Pancreatic Neoplasms
Completed—1
Phase 1PSI-352938
Hepatitis C
Completed
2012-01past
1
Phase 1GS-5806
RSV Infection
Completed
2013-04past
1
Phase 1GS-6615
Long QT Syndrome
Completed
2014-11past
1
Phase 1Voxilaprevir
Hepatitis C Virus Infection
Completed
2014-12-22past
1
Phase 1GS-9901
Follicular Lymphoma+3 more
Terminated
2015-08past
1
Phase 1SOF/VEL/VOX
HCV Infection
Completed
2016-03-18past
1
Phase 1Hu5F9-G4
Acute Myeloid Leukemia+1 more
Completed
2018-11past
1
Phase 1Firsocostat
Nonalcoholic Steatohepatitis (NASH)
Completed
2019-05-05past
1
Phase 1Atorvastatin
Rheumatoid Arthritis
Completed
2021-01-13past
1
Phase 1B/F/TAF
HIV-1-infection
Completed
2022-07-21past
1
Phase 1Edecesertib
Cutaneous Lupus Erythematosus
Terminated
2022-10-18past
1
Phase 1Vesatolimod
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Terminated
2023-05-01past
1
Phase 1Bulevirtide
Hepatic Impairment+1 more
Completed
2025-01-10past
1
Phase 1zamzetoclax
Solid Malignancies
Terminated
2025-06-16past
1
Phase 1GS-1219
HIV-1-infection
Terminated
2025-09-19past
1
Phase 1GS-3242
HIV-1-infection
Completed
2026-03-03past
1
Phase 1GS-2121
Advanced Solid Tumors
Recruiting
2028-06
1
N/AUnnamed
Hepatitis C, Chronic
Completed
2017-03-28past
1
N/AUnnamed
HIV Infection
Completed
2018-03-13past
1
N/AUnnamed
Breast Cancer
Completed
2025-07-28past
1
N/ATenofovir disoproxil fumarate
HIV Infections
Completed—1
N/ACidofovir
Cytomegalovirus Retinitis+1 more
Unknown—1
Valuation

Risk-adjusted NPV

Loading pipeline…
Peer comparison

Cohort check

Large-cap biotech · 5 tickers
Loading peers…
Cells tinted green are top-ranked in the cohort, red are worst-ranked.